Published in Int J Urol on January 07, 2009
Common uses and cited complications of energy in surgery. Surg Endosc (2013) 1.36
Current status of partial nephrectomy for renal mass. Korean J Urol (2011) 0.97
Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol (2008) 4.75
Generation of pluripotent stem cells from neonatal mouse testis. Cell (2004) 3.95
Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol (2007) 2.42
The state of prostate MRI in 2013. Oncology (Williston Park) (2013) 2.33
Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75. Urology (2009) 2.09
Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate. J Urol (2010) 2.05
Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland. J Urol (2009) 2.03
Promoter hypermethylation profile of kidney cancer. Clin Cancer Res (2004) 2.02
Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev (2008) 1.99
Current use of the artificial urinary sphincter and its long-term durability: a nationwide survey in Japan. Int J Urol (2009) 1.96
Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol (2012) 1.95
Bilateral focal ablation of prostate tissue using low-energy direct current (LEDC): a preclinical canine study. BJU Int (2013) 1.89
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol (2009) 1.85
Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. BJU Int (2007) 1.71
Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite. Cancer (2008) 1.71
Prevalence of fluoroquinolone-resistant Escherichia coli before and incidence of acute bacterial prostatitis after prostate biopsy. Urology (2011) 1.65
Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer (2010) 1.59
Factors predicting prostatic biopsy Gleason sum under grading. J Urol (2009) 1.59
L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int (2009) 1.57
High molecular mass proteome of androgen-independent prostate cancer. Proteomics (2005) 1.54
Complications of laparoscopic and percutaneous renal cryoablation in a single tertiary referral center. Eur Urol (2010) 1.53
Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer. Clin Trials (2008) 1.48
Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol (2002) 1.48
Current status of minimally invasive ablative techniques in the treatment of small renal tumours. Eur Urol (2006) 1.47
Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk. J Urol (2010) 1.45
Predicting occult multifocality of renal cell carcinoma. Eur Urol (2010) 1.45
The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. Biochem Biophys Res Commun (2009) 1.45
Predictors of benign histology in clinical T1a renal cell carcinoma tumors undergoing partial nephrectomy. Int J Urol (2013) 1.42
Surgical outcome of laparoscopic radical prostatectomy: summary of early multiinstitutional experience in Japan. Int J Clin Oncol (2003) 1.38
Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int (2011) 1.37
Derivation conditions impact X-inactivation status in female human induced pluripotent stem cells. Cell Stem Cell (2012) 1.35
Treatment of localised renal cell carcinoma. Eur Urol (2011) 1.29
Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer (2007) 1.27
Cell line-dependent differentiation of induced pluripotent stem cells into cardiomyocytes in mice. Cardiovasc Res (2010) 1.21
Isolation and characterization of bone marrow-derived mesenchymal progenitor cells with myogenic and neuronal properties. Exp Cell Res (2007) 1.20
Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. Urology (2009) 1.18
Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen. Urology (2008) 1.15
The endoscopic surgical skill qualification system in urological laparoscopy: a novel system in Japan. J Urol (2006) 1.13
alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer. Glycobiology (2009) 1.11
Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol (2010) 1.11
Complications after percutaneous radiofrequency ablation of renal tumors. Urology (2005) 1.10
Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. BJU Int (2008) 1.07
Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer? Urol Oncol (2009) 1.07
Acoustic radiation force impulse imaging of human prostates: initial in vivo demonstration. Ultrasound Med Biol (2011) 1.06
Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int (2009) 1.06
Quality of life after brachytherapy or radical prostatectomy for localized prostate cancer: a prospective longitudinal study. Urology (2006) 1.05
Acoustic radiation force impulse imaging of human prostates ex vivo. Ultrasound Med Biol (2010) 1.04
Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate cancer: a preliminary report. Urology (2002) 1.04
Characterizing stiffness of human prostates using acoustic radiation force. Ultrason Imaging (2010) 1.04
Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death. BJU Int (2010) 1.04
Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer (2011) 1.04
Anterior distribution of Stage T1c nonpalpable tumors in radical prostatectomy specimens. Urology (2002) 1.03
Update on cryotherapy for prostate cancer in 2006. Curr Opin Urol (2006) 1.03
Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended. BJU Int (2009) 1.01
Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol (2010) 0.99
Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience. Cancer (2010) 0.98
Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. Urology (2007) 0.98
Cigarette smoking is associated with advanced renal cell carcinoma. J Clin Oncol (2011) 0.98
Focal therapy for prostate cancer: possibilities and limitations. Eur Urol (2010) 0.97
Primary squamous cell carcinoma of the seminal vesicle. Urology (2002) 0.97
Prostate cancer: the new landscape. Curr Opin Urol (2009) 0.97
Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes? Urology (2009) 0.97
Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer. Urology (2007) 0.97
Cavernous hemangioma of the adrenal gland. Int J Urol (2009) 0.96
Immunohistochemical biomarkers for bladder cancer prognosis. Int J Urol (2011) 0.96
Identification of copy number alterations and its association with pathological features in clear cell and papillary RCC. Cancer Lett (2008) 0.96
Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity. Int J Radiat Oncol Biol Phys (2009) 0.96
A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. BJU Int (2010) 0.96
Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy. J Sex Med (2011) 0.96
Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer. Urology (2008) 0.95
Supplement use among men with prostate cancer. Urology (2005) 0.95
Cancer core distribution in patients diagnosed by extended transperineal prostate biopsy. Urology (2005) 0.95
Effect of freeze time during renal cryoablation: a swine model. J Endourol (2006) 0.95
[Spontaneous cervical epidural hematoma presenting with hemiparesis following neck extension: a case report]. No Shinkei Geka (2008) 0.94
[Superficial bladder cancer with lung metastasis without local invasion: a case report]. Hinyokika Kiyo (2007) 0.94
Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urology (2004) 0.94
Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center. J Urol (2011) 0.94
Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer (2003) 0.94
Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation. Orphanet J Rare Dis (2013) 0.94
Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project. BJU Int (2014) 0.93
Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guérin for superficial bladder cancer recurrence. Int J Urol (2003) 0.93
Changes in serum IgG oligosaccharide chains with prostate cancer progression. Anticancer Res (2004) 0.92
Effect of low-fat diets on plasma levels of NF-κB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. Cancer Prev Res (Phila) (2011) 0.92
Bone marrow engraftment but limited expansion of hematopoietic cells from multipotent germline stem cells derived from neonatal mouse testis. Exp Hematol (2009) 0.92
Clinical predictors of renal mass pathological features. BJU Int (2010) 0.92
A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy. J Clin Anesth (2009) 0.91
Histopathologic and biologic characteristics of a transitional cell carcinoma with inverted papilloma-like endophytic growth pattern. Urology (2003) 0.91
Management of small renal tumors with radiofrequency ablation. Urology (2003) 0.91
The effect of noise-cancelling headphones or music on pain perception and anxiety in men undergoing transrectal prostate biopsy. Urology (2012) 0.91
Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer. BJU Int (2010) 0.90
Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence? Urology (2009) 0.90
Identification of cardiac stem cells with FLK1, CD31, and VE-cadherin expression during embryonic stem cell differentiation. FASEB J (2005) 0.90
Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer (2002) 0.90
Difference in rectal dosimetry between pre-plan and post-implant analysis in transperineal interstitial brachytherapy for prostate cancer. Radiother Oncol (2006) 0.89
Prostatic cystadenoma presenting as a large multilocular mass. Int J Urol (2002) 0.89
Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis. BJU Int (2008) 0.89
Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. World J Urol (2012) 0.88